Pharmaceutical Companies Expanding mRNA Technology to Treat Influenza

Pharmaceutical Companies Expanding mRNA Technology to Treat Influenza
Three 10-dose influenza virus vaccine vials are seen at Ballin Pharmacy in Chicago, Illinois on Oct. 8, 2004. Tim Boyle/Getty Images
Meiling Lee
Updated:
0:00
News Analysis

Unlike other vaccines, influenza shots are administered yearly, yet offer generally lower protection than most routinely recommended vaccines, from as low as 10 percent to as high as 60 percent. This season’s flu jab was only 16 percent effective, according to the Centers for Disease Control and Prevention (CDC).